Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012;2(3):214-26. doi:10.1158/2159-8290.CD-12-0012
Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature. 2015;526(7573):336-42. doi:10.1038/nature15816
Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96. doi:10.1200/JCO.2010.33.2312
Delaney SK, Hultner ML, Jacob HJ, et al. Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn. 2016;16(5):521-32. doi:10.1586/14737159.2016.1146593
Van Allen EM, Pomerantz M. Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clin North Am. 2012;39(4):483-90. doi:10.1016/j.ucl.2012.07.005
Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol. 2016;26(3):231-9. doi:10.1097/MOU.0000000000000278
Palotie A, Widén E, Ripatti S. From genetic discovery to future personalized health research. N Biotechnol. 2013;30(3):291-5. doi:10.1016/j.nbt.2012.11.013
Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013;1(1):11-5. doi:10.1158/2326-6066.CIR-13-0022
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5. doi:10.1200/JCO.2013.49.4799
Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, et al. Towards patient-based cancer therapeutics. Nat Biotechnol. 2010;28(9):904-6. doi:10.1038/nbt0910-904